中药安全性评价理论创新与技术突破：病证毒理学

doi:10.19803/j.1672-8629.20230787

摘要/Abstract

摘要： 目的提出病证毒理学理论及方法体系,皆在促进病证毒理学在中药新药开发、中药临床安全性评价以及中药安全精准用药对策制定方面的科学、合理和高效运用,促进中医药事业健康可持续发展。方法结合病证毒理学实践运用情况,全面定义病证毒理学的外延和内涵,并系统梳理基于病证毒理学的中药安全性研究新理论、新方法和新发现。结果中药毒性主要分为固有毒性和特异质毒性2种类型,由于特异质毒性具有偶发性,易感性和难预测等特点,常规毒理学模式和方法难以评价,为此本团队传承创新中医“有故无殒”毒效思想,2016年首次提出病证毒理学理论和方法,皆在突破常规毒理学模式和方法局限性,科学厘清遗传、体质、疾病和证候等机体因素对中药安全性的影响规律和主次关系,解决中药特异质毒性评价难题。近年来,本团队在不断完善和优化病证毒理学理论和方法体系基础上,以临床真实世界和体内外病证易感模型为主要评价模式,开展了何首乌、补骨脂和淫羊藿等中药及及其相关制剂特异质毒性的易感人发现识别、成因机制解析及风险防控对策研究,破解了系列传统“无毒”中药安全性评价及风险防控难题。结论病证毒理学不仅可以用于特异质毒性中药的易感人群识别、成因机制解析以及风险防控对策研究,还可以用于固有毒性中药的“病（证）-量-时-毒-效”关系以及安全治疗窗研究。病证毒理学创新发展了中药毒理学理论和方法,为中药安全精准用药提供了奠基性理论和技术支撑。

关键词: 中药, 安全性, 病证毒理学, 毒性, 理论体系, 技术创新

Abstract: Objective To promote the scientific, rational and efficient application of disease-syndrome-based toxicology in the development of new traditional Chinese medicine drugs, the clinical safety evaluation of traditional Chinese medicine (TCM), and the formulation of safe and precise medicine countermeasures, and promote the healthy and sustainable development of TCM. Methods In combination with the application of disease-syndrome-based toxicology in practice, its extension and intension were comprehensively defined. Meanwhile, the new theories, methods and discoveries of TCM safety research based on disease-syndrome-based toxicology were systematically reviewed. Results The toxicity of TCM is mainly divided into two types: intrinsic toxicity and idiosyncratic toxicity. Due to the sporadicity, susceptibility and unpredictability of idiosyncratic toxicity, conventional toxicological models and methods are difficult to evaluate the idiosyncratic toxicity of TCM. Therefore, the author's team inherited and innovated the idea of "You Gu Wu Yun" in TCM theory, and proposed the theory and method of disease-syndrome-based toxicology for the first time in 2016, aiming to break through the limitations of conventional toxicological models and methods, scientifically clarify the influence of factors such as heredity, constitution, disease syndrome, and other factors on the safety of TCM, and solve the problem of evaluating the idiosyncratic toxicity of TCM. In recent years, based on the continuous improvement and optimization of the disease-syndrome-based toxicology theory and methodological system, the author's team used the clinical real-world and the in vivo and in vitro susceptibility model of disease and syndrome as the main evaluation model, and carried out the research on the identification of susceptible population, genetic mechanism analysis and risk prevention and control countermeasures of the idiosyncratic toxicity of TCM such as Polygonum multiflorum, Fructus Psoraleae and Herba Epimedii, which solved the problems of safety evaluation and risk prevention and control of a series of traditional “non-toxic” TCM. Conclusion Disease-syndrome-based toxicology can not only be used for the identification of susceptible populations, mechanism analysis, and risk prevention and control strategies of TCM with idiosyncratic toxicity, but also for the study of the “disease (syndrome)-dose-time-toxicity-effect” relationship and safe therapeutic window of TCM with intrinsic toxicity.

Key words: traditional Chinese medicine, safety, disease-syndrome-based toxicology, toxicity, theoretical system, technological innovation

中图分类号:

R994.11

柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.

BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230787

https://www.zgywjj.com/CN/Y2024/V21/I1/6

参考文献

[1] XIAO XH, BAI ZF, WANG JB, et al.Traditional Chinese medicine(TCM) safety evaluation and pharmacovigilance[J]. Chinese Science Bulletin(科学通报), 2021, 66(Z1): 407-414.
[2] ZHAO ZH, ZHANG L, LI WB, et al.Research progress on safety evaluation and toxicity of traditional Chinese medicine[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2018, 24(20): 208-216.
[3] WANG M, HU WJ, ZHOU X, et al.Ethnopharmacological use, pharmacology, toxicology, phytochemistry, and progress in Chinese crude drug processing of the lateral root of Aconitum carmichaelii Debeaux.(Fuzi): a review[J]. Journal of Ethnopharmacology, 2023, 301: 115838.
[4] LUO ZC, ZHANG W, YANG R, et al.Research progress on biopharmaceutical the study of mechanism of Glycyrrhiza uralensis Fisch "moderating property of herbs"[J]. Chinese Traditional and Herbal Drugs(中草药), 2021, 52(1): 267-277.
[5] WANG JB, CUI HR, BAI ZF, et al.Precision medicine-oriented safety assessment strategy for traditional Chinese medicines: disease-syndrome-based toxicology[J]. Acta Pharmaceutica Sinica(药学学报), 2016, 51(11): 1681-1688.
[6] HOOFNAGLE JH, BJÖRNSSON ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273.
[7] GAO YJ, ZHAO X, BAI ZF, et al.Prevention and control of safety risks of traditional Chinese medicine based on indirect knowledge of toxicity[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(11): 1004-1008.
[8] BAI ZF, WANG JB, XIAO XH.Cognition innovation of toxicity of Chinese medicine and safe and precise medication[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2022, 47(10): 2557-2564.
[9] WANG JB, LI CY, ZHU Y, et al.Integrated evidence chain-based identification of Chinese herbal medicine-induced hepatotoxicity and rational usage: exemplification by Polygonum Multiflorum(He shou wu)(in Chinese)[J]. Chin Sci Bull(科学通报), 2016, 61: 971-980.
[10] ZHU Y, LIU SH, WANG JB, et al.Clinical analysis of drug-induced liver injury caused by polygonum multiflorum and its preparations B[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2015, 35(12): 1442-1447.
[11] TU C, GE FL, GUO YM, et al.Analysis of clinical characteristics and medication rationality of polygonum multiflorum thunb. and its preparation-related liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(5): 270-276.
[12] LI C, RAO T, CHEN X, et al.HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357.
[13] TU C, NIU M, WEI AW, et al.Susceptibility-related cytokine panel for prediction of polygonum multiflorum-induced hepatotoxicity in humans[J]. J Inflamm Res, 2021, 14: 645-655.
[14] ZHANG L, NIU M, WEI AW, et al.Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum[J]. Arch Toxicol, 2020, 94(1): 245-256.
[15] BAI ZF, GAO Y, WANG JB, et al.Evaluation and risk control of idiosyncratic liver injury caused by traditional Chinese medicine[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(10): 724-729.
[16] BAI ZF, GAO Y, ZUO XB, et al.Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(7): 1019-1026.
[17] METUSHI IG, HAYES MA, UETRECHT J.Treatment of PD-1^-/-mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients[J]. Hepatology, 2015, 61(4): 1332-1342.
[18] MAK A, UETRECHT J.The role of CD8 T cells in amodiaquineinduced liver injury in PD¹-/-mice cotreated with antiCTLA-4[J]. Chem Res Toxicol, 2015, 28(8): 1567-1573.
[19] CARDONE M, GARCIA K, TILAHUN ME, et al.A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity[J]. J Clin Invest, 2018,128(7): 2819-2832.
[20] ONG MM, WANG AS, LEOW KY, et al.Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/-) mice[J]. Free Radic Biol Med, 2006, 40(3): 420-429.
[21] LEE YH, CHUNG MC, LIN Q, et al.Troglitazoneinduced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury[J]. Toxicol Appl Pharmacol, 2008, 231(1): 43-51.
[22] D'UGO E, ARGENTINI C, GIUSEPPETTI R, et al. The woodchuck hepatitis B virus infection model for the evaluation of HBV therapies and vaccine therapies[J]. Expert Opin Drug Discov, 2010, 5(12): 1153-1162.
[23] KOSINSKA AD, LIU J, LU M, et al.Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck[J]. Med Microbiol Immunol, 2015, 204(1): 103-114.
[24] KNAPP AC, TODESCO L, BEIER K, et al.Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores[J]. J Pharmacol Exp Ter, 2008, 324(2): 568-575.
[25] LUYENDYK JP, MADDOX JF, COSMA GN, et al.Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats[J]. J Pharmacol Exp Ther, 2003, 307(1): 9-16.
[26] DENG X, STACHLEWITZ RF, LIGUORI MJ, et al.Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation[J]. J Pharmacol Exp Ther, 2007, 319(3): 1191-1199.
[27] BUCHWEITZ JP, GANEY PE, BURSIAN SJ, et al.Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?[J]. J Pharmacol Exp Ther, 2002, 300(2): 460-467.
[28] SHAW PJ, HOPFENSPERGER MJ, GANEY PE, et al.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factoralpha[J]. Toxicol Sci, 2007, 100(1): 259-266.
[29] DUGAN CM, MACDONALD AE, ROTH RA, et al.A mouse model of severe halothane hepatitis based on human risk factors[J]. J Pharmacol Exp Ther, 2010, 333(2): 364-372.
[30] SHAW PJ, FULLERTON AM, SCOTT MA, et al.The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability[J]. Toxicol Appl Pharmacol, 2009, 236(3): 293-300.
[31] SHAW PJ, GANEY PE, ROTH RA.Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus resulting in neutrophil-dependent liver injury in mice[J]. J Pharmacol Exp Ter, 2009, 330(1) : 2-78.
[32] CHENG L, YOU Q, YIN H, et al.Effect of polyI: C cotreatment on halothane-induced liver injury in mice[J]. Hepatology, 2009, 49(1): 215-226.
[33] LI CY, LI XF, TU C, et al.The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model[J]. Acta Pharm Sin(药学学报), 2015, 50: 28-33.
[34] HE LZ, YIN P, MENG YK, et al.Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu related idiosyncratic liver injury[J]. Sci Bull, 2017, 62(11): 748-751.
[35] BAI ZF, HE LZ, MENG YK, et al.Immune idiosyncratic liver injury induced by traditional non-toxic traditional Chinese medicine and a hypothesis of its mechanism[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2017, 52(13): 1105-1109.
[36] GAO Y, WANG ZL, TANG JF, et al.New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front Med, 2020, 14(1): 68-80.
[37] QIN N, XU G, WANG Y, et al.Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity[J]. Front Med, 2021, 15(4): 594-607.
[38] WANG Y, XU G, WANG Z, et al.Psoralidin, a major component of Psoraleae Fructus, induces inflammasome activation and idiosyncratic liver injury[J]. Int Immunopharmacol, 2021, 92: 107352.
[39] LIU T, XU G, LI Y, et al.Discovery of bakuchiol as an AIM2 inflammasome activator and cause of hepatotoxicity[J]. J Ethnopharmacol, 2022, 298: 115593.
[40] GAO Y, XU G, MA L, et al.Icarisid I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity[J]. Cell Commun Signal, 2021, 19(1): 13.
[41] WANG ZL, XU G, WANG HB, et al.Icariside II, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation[J]. Acta Pharm Sin B, 2020, 10(9): 1619-1633.
[42] GAO Y, SHI W, TU C, et al.Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim[J]. Front Pharmacol, 2022, 13: 1015846.
[43] ZHANG ML, ZHAO X, LI WX, et al.Yin/Yang associated differential responses to Psoralea corylifolia Linn. In rat models: an integrated metabolomics and transcriptomics study[J]. Chin Med, 2023, 18(1): 102.
[44] Branch of Chinese Patent Medicine, China Association of Chinese Medicine, Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Committee of Clinical Chinese Pharmacy, Chinese Pharmaceutical Association, et al. Guidelines for safe use of Polygoni Multiflori Radix[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(5): 961-966.
[45] WANG YX, LIU B, SHI RB, et al.Research on quality control method of stilbene fraction of Polygonum multifl orum Thunb[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志) , 2009, 24(10): 1277-1280.
[46] ZHANG L, BAI ZF, LI CY, et al.Study on idiosyncratic liver injury and content of cis-2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside in radix Polygoni multiflori Preparata[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(7): 1041-1047.
[47] SONG D, CHEN SS, LI PY, et al.Attenuating the potential hepatotoxicity of Psoraleae Fructus by pre-processing: the alcohol soaking and water rinsing method[J]. Acta Pharmaceutica Sinica(药学学报), 2020, 55(2): 276-282.
[48] SHI W, LIU T, YANG H, et al.Isomaculosidine facilitates NLRP3 inflammasome activation by promoting mitochondrial reactive oxygen species production and causes idiosyncratic liver injury[J]. J Ethnopharmacol, 2024, 319(Pt 1): 117063.
[49] WANG Z, XU G, ZHAN X, et al.Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice[J]. Arch Toxicol, 2019, 93(12): 3585-3599.
[50] MU W, XU G, WANG Z, et al.Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation[J]. Cell Commun Signal, 2023, 21(1): 123.
[51] FU SB, XU G, GAO Y, et al.Inhibitory effect and mechanism of licochalcone A on NLRP3 inflammasome[J]. Acta Pharmaceutica Sinica(药学学报), 2018, 53(12): 2050-2056.
[52] LI Q, FENG H, WANG H, et al.Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction[J]. EMBO Rep, 2022, 23(2): e53499.
[53] XU G, FU S, ZHAN X, et al.Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90[J]. JCI Insight, 2021, 6(2): e134601.
[54] LIU H, ZHAN X, XU G, et al.Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases[J]. Pharmacol Res, 2021, 164: 105384.
[55] ZHAO J, LIU H, HONG Z, et al.Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC[J]. Mol Med, 2023, 29(1): 84.
[56] SONG HB, SHEN CY.Exploring the safe use and risk management of traditional chinese medicine-a case study of polygonum multiflorum risk management[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2020, 12: 12-18.